BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Dupilumab: trial readouts and FDA decisions
0 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 5 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sanofi, AbbVie, Regeneron Pharmaceuticals, Innovent Biologics (Suzhou) Co. Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | AbbVie ABBV | NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis | active not recruiting | 184 |
| 2026-10-09 | P3 | Regeneron Pharmaceuticals REGN | NCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 880 |
| 2026-08-18 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | terminated | 18 |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687980 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 138 |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687967 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 142 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.